A Phase I double-blind, placebo-controlled, single ascending dose study for LX-9211 in healthy volunteers.

Trial Profile

A Phase I double-blind, placebo-controlled, single ascending dose study for LX-9211 in healthy volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs LX 9211 (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 08 Nov 2017 According to a Lexicon Pharmaceuticals media release, data from this trial is expected in 2018.
    • 27 Sep 2017 According to a Lexicon Pharmaceuticals media release, the company has initiated dosing in a Phase I study.
    • 27 Sep 2017 Status changed from planning to recruiting, according to a Lexicon Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top